The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anti-tumor activity of RP12146, a PARP1/2 inhibitor, in patients with metastatic castration-resistant prostate cancer.
 
Piotr Jan Wysocki
Honoraria - Immunicom Inc
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb/Medarex; Immunicom; Janssen; MSD Oncology; Pierre Fabre; Roche
Expert Testimony - Immunicom; Immunicom
Travel, Accommodations, Expenses - Gilead Sciences; Immunicom; Pierre Fabre
 
Maciej Tadeusz Lubaś
No Relationships to Disclose
 
Mateusz Łobacz,
No Relationships to Disclose
 
Ewa Kalinka
No Relationships to Disclose
 
Piotr Tomczak
No Relationships to Disclose
 
Michal Kwiatek
No Relationships to Disclose
 
Iwona A. Lugowska
Honoraria - Agenus; Amgen; AstraZeneca; BeiGene; BMS; Celon Pharma; Cullinan Oncology; Jacobio; Janssen; Loxo; Macrogenics; Menarini; MSD; Pfizer; Rhizen Pharmaceuticals; ROCHE; Sanofi; Sanofi; Takeda
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AGENUS (Inst); ROCHE (Inst)
Travel, Accommodations, Expenses - BMS
 
Dominik Chraniuk
No Relationships to Disclose
 
Prajak J. Barde
Consulting or Advisory Role - Rhizen Pharmaceuticals
 
Swaroop V.S. Vakkalanka
Stock and Other Ownership Interests - Rhizen Pharmaceuticals
 
Martin Smakal
No Relationships to Disclose